ONC · BeOne Medicines Ltd. · Webcasts, Transcripts & Audio
$416.54
+0.58 (+0.14%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$47.58B
Shares
114.23M
Volume · Nov 13
345.46K
Avg daily vol (3M)
404.68K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
BeOne Medicines Ltd. Webcasts
Earnings calls, investor updates, investor days and conferences for BeOne Medicines Ltd. (ONC), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
BeOne Medicines Ltd. (ONC) Q3 2026 Earnings Call
Revenue
$1.89B
▲ 33.8% YoY Diluted EPS
$0.25
▲ 212.5% YoY Gross margin
88.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
BeOne Medicines Ltd. (ONC) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-09-14
BeOne Medicines Ltd. (ONC) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-05
BeOne Medicines Ltd. (ONC) Q2 2026 Earnings Call Transcript
Revenue
$1.71B
▲ 29.6% YoY Diluted EPS
$0.16
▲ 166.7% YoY Gross margin
89.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-08
BeOne Medicines Ltd. (ONC) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
BeOne Medicines Ltd. (ONC) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-06
BeOne Medicines Ltd. (ONC) Q1 2026 Earnings Call
Revenue
$1.51B
▲ 35.5% YoY Diluted EPS
$0.15
Gross margin
89.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
BeOne Medicines Ltd. (ONC) Q4 2025 Earnings Call Transcript
Confident tone
BRUKINSA franchise leadership in CLL
Fixed-duration vs continuous treatment dynamics
Pipeline progress and R&D momentum
Revenue
$1.50B*
▲ 32.8% YoY Gross margin
90.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-06
BeOne Medicines Ltd. (ONC) Q3 2025 Earnings Call Transcript
Confident tone
Sonro (BCL2 inhibitor) and zanu+sonro combination
BRUKINSA commercial momentum and global leadership
ASH 2025 data presentations and scientific leadership
Revenue
$1.41B
▲ 41% YoY Diluted EPS
$0.08
Gross margin
86.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
BeOne Medicines Ltd. (ONC) Q2 2025 Earnings Call Transcript
Confident tone
BRUKINSA commercial leadership
CLL franchise and ALPINE data
Financial results and cash flow
Revenue
$1.32B
▲ 41.6% YoY Diluted EPS
$0.06
Gross margin
87.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
BeOne Medicines Ltd. (ONC) Q1 2025 Earnings Call Transcript
Confident tone
Global commercial expansion
BRUKINSA commercial leadership
Pipeline progression
Revenue
$1.12B
▲ 48.6% YoY Diluted EPS
$0.00
Gross margin
85.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
BeOne Medicines Ltd. (ONC) Q4 2024 Earnings Call
Revenue
$1.13B*
▲ 77.8% YoY Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-12-16
BeOne Medicines Ltd. (ONC) Q3 2024 Earnings Call
Revenue
$1.00B
▲ 28.2% YoY Diluted EPS
$-0.09
▼ 160% YoY Gross margin
83.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
BeOne Medicines Ltd. (ONC) Q2 2023 Earnings Call
Revenue
$595.26M
▲ 74.3% YoY Diluted EPS
$-0.28
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–14 of 14 webcasts
Key facts
CIK
1651308
CUSIP
07725L102
13F (30d)
269 filings
245 filers
Visit website
Investor relations